Mark Rau

In my role as Market Intelligence Analyst I gather, analyze and consolidate information to support pro-active, fact-based decision making for our Comparator service line within the Clinical Trial Divison: - Global drug pricing & availability - Biosimilars & generics availabililty and patent expiry - Drug supplier network mapping for both innovators and wholesale - KPI tracking - Sourcing (costs, savings, supplier performance & quality) - Tailored market intelligence reports

Assessing the treatment options of non-muscle invasive bladder cancer and its immune environment in the context of BCG infection Methods: FACS and fluorescence imaging Extracurricular activities: extensive courses in immunology and cancer research, teaching

In-vitro: RNA- und proteinlevel quantification of immune cell lines after treatment with transcription inhibitors

Development of <3 min/sample method to screen and identify 40 different anxiolytic compounds (benzodiazepines and z-drugs) and their metabolites. Subsequent validation according to FDA/EMA regulations

Search for novel neurophatic pain drug candidates: Collaboration with Hoffman La Roche and ETH Zurich for the development of novel modulators of the endocannabinoid system in the framework of the Transcure Network. In vitro screening and validation of several iterations of algorithm assisted compound SAR presentation of results and MedChem adaptions on functional groups

Phyto extract screening for new drug leads: Screening of 446 medicinal plant extract library in collaboration with Schwabe Pharmaceuticals for novel mechanisms of the endocannabinoid system